Yale University

The cost of integrated HIV care and buprenorphine/naloxone treatment: results of a cross-site evaluation.

TitleThe cost of integrated HIV care and buprenorphine/naloxone treatment: results of a cross-site evaluation.
Publication TypeJournal Article
Year of Publication2011
AuthorsSchackman, Bruce R., Jared A. Leff, Michael Botsko, David A. Fiellin, Fredrick L. Altice, Todd P. Korthuis, Nancy Sohler, Linda Weiss, James E. Egan, Julie Netherland, Jonathan Gass, and Ruth Finkelstein
Corporate AuthorsBHIVES Collaborative
JournalJournal of acquired immune deficiency syndromes (1999)
Volume56 Suppl 1
PaginationS76-82
Date Published2011 Mar 1
ISSN1944-7884
KeywordsAnti-HIV Agents, Buprenorphine, Delivery of Health Care, Integrated, Health Care Costs, HIV Infections, Humans, Naloxone, Narcotic Antagonists, Opioid-Related Disorders
AbstractImplementing integrated HIV and buprenorphine/naloxone treatment requires cost estimates to plan and obtain funding.
DOI10.1097/QAI.0b013e31820a9a66
Alternate JournalJ. Acquir. Immune Defic. Syndr.

External Links